ASCO20: Adding Local Stereotactic Radiotherapy to TKI in Oligometastatic Lung Cancer
Posted: Thursday, June 11, 2020
According to findings from the SINDAS trial presented during the ASCO20 Virtual Scientific Program (Abstract 9508), a combination of upfront stereotactic local radiotherapy and first-line tyrosine kinase inhibitor (TKI) treatment may result in better survival benefits versus TKI monotherapy. The phase III trial included patients with previously untreated EGFR-mutant oligometastatic non–small cell lung cancer.
“This finding suggests aggressive local therapy to sites at diagnosis should be explored further in large cohort phase III trials as a standard treatment option in this clinical scenario,” concluded Ming Zeng, MD, of the Sichuan Provincial People’s Hospital in China, and colleagues.
Between January 2016 and January 2019, 133 patients were randomly assigned to receive either TKI monotherapy (n = 65) or stereotactic radiotherapy plus TKI treatment (n = 68). At a median follow-up of 19.6 months, the radiotherapy group experienced a significantly higher median progression-free survival of 20.2 months versus 12.5 months. The median overall survival was also superior in the radiotherapy arm at 25.5 months versus 17.4 months.
Neither group experienced treatment-related death or a grade 5 adverse event. The most common grade 3 or 4 adverse events included pneumonitis (7.3% with radiotherapy vs. 2.9% without) and esophagitis (4.4% vs. 3.0% without).
Disclosure: For full disclosures of the study authors, visit meetinglibrary.asco.com.
